Pura Vida Investments’s Exagen XGN Stock Holding History

Pura Vida Investments’s Portfolio XGN Stock Details XGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-51,502	Closed	-$772K	–	334
2021 Q2	$772K	Sell	51,502 -279,639	-84%	-$4.29M	0.02%	191
2021 Q1	$5.79M	Buy	+331,141	New	+$5.9M	0.17%	112

Other funds holding XGN

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SAM

Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Samjo Capital New York $254M AUM 36.81% 1-Year Est. Return

Pura Vida Investments's XGN Position: Q3 2021 in Review

Pura Vida Investments sold out of Exagen (XGN) in Q3 2021, closing a stake of 51,502 shares — an estimated $772K sold.

Pura Vida Investments first reported a position in XGN in Q1 2021 and held it in 2 quarters. The position peaked at $5.79M in Q1 2021. 53 funds tracked by Wall St. Rank hold XGN as of Q3 2021.

Pura Vida Investments reported no remaining Exagen position as of Q3 2021 after selling out during the quarter.
Pura Vida Investments sold 51,502 Exagen shares in Q3 2021, an estimated $772K.
Pura Vida Investments first reported a position in Exagen in Q1 2021 and held it in 2 quarters.
Pura Vida Investments's Exagen position peaked at $5.79M in Q1 2021.
53 funds tracked by Wall St. Rank held Exagen as of Q3 2021.

Based on Pura Vida Investments's 13F filing for Q3 2021, filed 15 Nov 2021.